Exclusive: Autoimmune CAR-T biotech Kyverna Therapeutics is considering an IPO next month
Kyverna Therapeutics, one of the clinical-stage biotechs at the forefront of CAR-T cell therapy’s expansion into autoimmune diseases, is considering an IPO as early as next month, people familiar with the company’s thinking told Endpoints News.
The California biotech could seek a listing shortly before Valentine’s Day, according to the individuals, who asked not to be identified to discuss confidential matters. The company could reveal its IPO filing as early as next week, though it’s also possible that plans could change.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.